Cefiderocol and Moxifloxacin Have Additive and Synergistic Activity Against Pseudomonas aeruginosa Including an Isolate of the 2023 Keratitis Outbreak
Investigative Ophthalmology & Visual Science · 2025-11-12 · 66 (14) · 19
DOI: 10.1167/iovs.66.14.19 ↗At a glance
Journal article in Investigative Ophthalmology & Visual Science, published on 2025-11-12. Written by Eric G Romanowski and 5 co-authors. Institution: Charles T. Campbell Laboratory, Department of Ophthalmology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States. Major MEDLINE topics: Pseudomonas aeruginosa, Moxifloxacin, Eye Infections, Bacterial, Pseudomonas Infections. Cited 3 times so far (Crossref); 33 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NEI NIH HHS.
Abstract (original language)
Purpose
The 2023 outbreak of Pseudomonas aeruginosa keratitis linked to contaminated artificial tears highlighted the need for new treatments targeting ocular infections caused by multi-drug-resistant and extensively drug-resistant bacteria. This study evaluated the in vitro efficacy and potential synergy of cefiderocol and moxifloxacin against P. aeruginosa keratitis isolates. The influence of quorum-sensing defects on antibiotic efficacy was also assessed because of the increase in lasR mutant keratitis isolates. Ceftazidime, which lacks the "Trojan Horse" iron-binding-mediated bacterial entry mechanism of cefiderocol, served as a comparator.
Methods
Time-kill and epsilometer (E-test) assays were used to determine minimum inhibitory concentrations and drug interactions. Fractional inhibitory concentration indices were calculated to characterize drug interactions as antagonistic, indifferent, additive, or synergistic. Quorum-sensing defective strains were identified by a characteristic colony sheen phenotype associated with LasR system defects.
Results
Time-kill studies demonstrated consistent synergistic interactions between cefiderocol and moxifloxacin against seven out of seven tested P. aeruginosa keratitis isolates, including one from the 2023 outbreak. E-test-based assays showed additive or synergistic activity against 79% of isolates, although this dropped to 60% among suspected quorum-sensing defective strains. In contrast, the ceftazidime and moxifloxacin combination was less effective, particularly sheen-positive strains. The cefiderocol-moxifloxacin combination showed indifferent effects against Serratia marcescens and Staphylococcus aureus, with each antibiotic retaining individual activity.
Conclusions
Cefiderocol and moxifloxacin exhibited synergy against most tested P. aeruginosa keratitis isolates in vitro, including those with suspected quorum-sensing defects. These findings support further investigation of this combination for treating highly drug-resistant ocular infections.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Charles T. Campbell Laboratory, Department of Ophthalmology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States.
- Department of Surgery, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, United States.
Funding
- NEI NIH HHS
Cite
APA
Romanowski, E. G., Schilling, B. M., Young, E. K., Mumper, S. M., Zegans, M. E., & Shanks, R. M. Q. (2025). Cefiderocol and Moxifloxacin Have Additive and Synergistic Activity Against Pseudomonas aeruginosa Including an Isolate of the 2023 Keratitis Outbreak. Investigative Ophthalmology & Visual Science, 66(14), 19. https://doi.org/10.1167/iovs.66.14.19
Vancouver
Romanowski EG, Schilling BM, Young EK, Mumper SM, Zegans ME, Shanks RMQ. Cefiderocol and Moxifloxacin Have Additive and Synergistic Activity Against Pseudomonas aeruginosa Including an Isolate of the 2023 Keratitis Outbreak. Investigative Ophthalmology & Visual Science. 2025;66(14):19. doi:10.1167/iovs.66.14.19
BibTeX
@article{Romanowski2025,
author = {Romanowski, Eric G and Schilling, Brennan M and Young, Emily K and Mumper, Sonya M and Zegans, Michael E and Shanks, Robert M Q},
title = {Cefiderocol and Moxifloxacin Have Additive and Synergistic Activity Against Pseudomonas aeruginosa Including an Isolate of the 2023 Keratitis Outbreak},
journal = {Investigative Ophthalmology & Visual Science},
year = {2025},
volume = {66},
number = {14},
pages = {19},
doi = {10.1167/iovs.66.14.19}
}
EUVIMED